In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? Yes; we must beware of drawing conclusions from a subset analysis

Daniel L. Suzman; Emmanuel S. Antonarakis

In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? Yes; we must beware of drawing conclusions from a subset analysis

Daniel L. Suzman, Emmanuel S. Antonarakis

School of Medicine

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Journal	Oncology (United States)
Volume	28
Issue number	10
State	Published - Oct 15 2014

ASJC Scopus subject areas

Oncology
Cancer Research

Cite this

@article{650b8c3f62224d69be1bc34dc3b64501,

title = "In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? Yes; we must beware of drawing conclusions from a subset analysis",

author = "Suzman, {Daniel L.} and Antonarakis, {Emmanuel S.}",

year = "2014",

month = oct,

day = "15",

language = "English (US)",

volume = "28",

journal = "Oncology (United States)",

issn = "0890-9091",

publisher = "UBM Medica Healthcare Publications",

number = "10",

}

TY - JOUR

T1 - In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? Yes; we must beware of drawing conclusions from a subset analysis

AU - Suzman, Daniel L.

AU - Antonarakis, Emmanuel S.

PY - 2014/10/15

Y1 - 2014/10/15

UR - http://www.scopus.com/inward/record.url?scp=84910029935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84910029935&partnerID=8YFLogxK

M3 - Comment/debate

C2 - 25323614

AN - SCOPUS:84910029935

SN - 0890-9091

VL - 28

JO - Oncology (United States)

JF - Oncology (United States)

IS - 10

ER -

In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? Yes; we must beware of drawing conclusions from a subset analysis

ASJC Scopus subject areas

Other files and links

Cite this